Tag:

AstraZeneca

Latest Headlines

Latest Headlines

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.

Could the cunning use of CVRs save a Pfizer-AstraZeneca merger?

With AstraZeneca's CFO telling investors that Pfizer's colossal takeover bid failed purely because it was too cheap, creative dealmakers are looking at new ways to get the two parties shaking hands.

AstraZeneca sponsors diabetes patient registry

The emergence of electronic health records has made it possible to build a more complete picture of the health of populations. To realize this vision for diabetes patients, AstraZeneca has signed up to sponsor a registry that gathers data from primary care physicians and specialists in other fields.

FDA panel advises against more clinical trials for opioid constipation drugs

An FDA panel today advised the agency against requiring more large clinical studies for the cardiovascular risks of drugs that treat opioid-induced constipution, relieving drugmakers like AstraZeneca, Salix Pharmaceuticals and others from bearing the burden of further clinical safety trials.

Pfizer lost its AstraZeneca bid purely on price, CFO says. What else?

Want to know why the potential Pfizer-AstraZeneca marriage failed? Price, says Pfizer CFO Frank D'Amelio. Stating the obvious, obviously. But in balking at Pfizer's offer, AstraZeneca--and allies in the U.K.--raised plenty of other issues. Emotional issues, for some.

AstraZeneca extends global shopping spree with $232M asthma drug deal

AstraZeneca's executive crew extended one of the biggest shopping sprees in the industry with a pact, in-licensing rights to a drug from Synairgen that targets the viral infections that afflict the respiratory tracts of asthma patients. And the little biotech's shares soared on the news.

AstraZeneca investors press exec-comp chair to tie pay to Pfizer bid

Several top AstraZeneca shareholders are pressing for meetings with John Varley, the former CEO of Barclays bank who also happens to head up the drugmaker's remuneration committee, Sky News reports. The aim? To follow through on calls to link AstraZeneca executive pay to the value of Pfizer's rejected buyout offer.

Rebel AstraZeneca investors push plan to tie exec pay to rosy R&D projections

AstraZeneca's executive team under CEO Pascal Soriot confidently batted down Pfizer's $120 billion takeover bid by putting an extraordinary valuation on its pipeline, often far exceeding the most optimistic forecasts by industry analysts. And now there appears to be a growing movement among a group of disenchanted investors at the U.K. company to hold management's incentive packages hostage to the sky-high expectations they've created.

AstraZeneca will tap Cancer Genetics' biomarker testing tech in Central America

New Jersey's Cancer Genetics will supply cancer-related biomarker-based testing for AstraZeneca, underscoring the ever-increasing alliance Big Pharma is forming with molecular diagnostics companies as the sector expands services and advances new drug development programs.

FDA to vote on opioid-induced constipation pills

The FDA has announced it will vote this week on whether a class of drugs that treat opioid-induced constipation needs more clinical testing in light of a side effect: heart attack. The class of drugs includes recently approved products from Salix Pharmaceuticals and Cubist Pharmaceuticals but also one that AstraZeneca is developing with Nektar Theraputics.